个人中心 - 老虎社区

4f4c837

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- 4f4c8374f4c837
  ·2021-12-22
  Interesting
  非常抱歉，此主贴已删除
  3,095 1
  2
  分享
  举报
- 4f4c8374f4c837
  ·2021-12-22
  Interesting
  非常抱歉，此主贴已删除
  3,036 评论
  2
  分享
  举报
- 4f4c8374f4c837
  ·2021-12-22
  Interesting
  10 Biggest Price Target Changes For Wednesday<blockquote>周三 10 大价格目标变化</blockquote>
  Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc
  10 Biggest Price Target Changes For Wednesday<blockquote>周三 10 大价格目标变化</blockquote>
  3,575 评论
  1
  分享
  举报
- 4f4c8374f4c837
  ·2021-12-22
  Interesting
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>
  Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s
  Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>
  2,837 评论
  点赞
  分享
  举报
- 4f4c8374f4c837
  ·2021-12-22
  Interesting
  Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>
  Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes ra
  Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>
  3,265 1
  3
  分享
  举报
- 4f4c8374f4c837
  ·2021-12-22
  Interesting
  非常抱歉，此主贴已删除
  4,003 评论
  4
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"4089174425482880","uuid":"4089174425482880","gmtCreate":1626139762421,"gmtModify":1640189757944,"name":"4f4c837","pinyin":"meowier","introduction":"","introductionEn":"","signature":"","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":14,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-3","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"偶像虎友","description":"加入老虎社区1500天","bigImgUrl":"https://static.tigerbbs.com/8b40ae7da5bf081a1c84df14bf9e6367","smallImgUrl":"https://static.tigerbbs.com/f160eceddd7c284a8e1136557615cfad","grayImgUrl":"https://static.tigerbbs.com/11792805c468334a9b31c39f95a41c6a","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2026.04.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLinkType":null,"redirectLink":null,"redirectLinkValidityFrom":null,"redirectLinkValidityTo":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100,"isScarce":0,"effectConfig":null,"effectEnabled":0,"plateImgUrl":null,"plateColors":null,"validityTo":null,"validityToTimestamp":null,"wearingSort":0}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":691625975,"gmtCreate":1640186032395,"gmtModify":1640186032395,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"title":"","htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691625975","repostId":"2193192429","repostType":4,"isVote":1,"tweetType":1,"viewCount":3095,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622121,"gmtCreate":1640185928643,"gmtModify":1640185971826,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"title":"","htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622121","repostId":"2193196162","repostType":4,"isVote":1,"tweetType":1,"viewCount":3036,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691622066,"gmtCreate":1640185916183,"gmtModify":1640185916183,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"title":"","htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691622066","repostId":"1188142807","repostType":4,"repost":{"id":"1188142807","kind":"news","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga Earnings","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1640181395,"share":"https://www.laohunote.com/m/news/1188142807?lang=zh_CN&edition=full","pubTime":"2021-12-22 21:56","market":"us","language":"en","title":"10 Biggest Price Target Changes For Wednesday<blockquote>周三 10 大价格目标变化</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1188142807","media":"Benzinga Earnings","summary":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Researc","content":"<p><ul>  <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>  <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>  <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>  <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>  <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>  <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>  <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>  <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>事实集研究系统公司。</b>从450美元到550美元。FactSet Research 股价在盘前交易中上涨 1.1%，至 479.89 美元。</li><li>HC Wainwright &amp; Co. 上调目标价<b>奇美里克斯公司。</b>从21美元到24美元。Chimerix 股价在盘前交易中上涨 4.4%，至 6.42 美元。</li><li>伯恩斯坦提出<b>帕卡公司</b>目标价从94美元到98美元。PACCAR 股价在盘前交易中上涨 0.8%，至 84.04 美元。</li><li>杰富瑞切割<b>柔板治疗公司。</b>目标价从46美元到10美元。Adagio Therapeutics 股价在盘前交易中下跌 7.3%，至 9.54 美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨 0.2%，至 166.98 美元。</li><li>李约瑟下调了目标价<b>认知软件有限公司</b>从36美元到19美元。Cognyte Software 股价在盘前交易中下跌 1%，至 15.54 美元。</li><li>杰富瑞切割<b>ALX肿瘤控股公司。</b>目标价从65美元到25美元。ALX Oncology Holdings 股价在盘前交易中下跌 1.5%，至 22.57 美元。</li><li>伯恩斯坦下调了目标价<b>爱科公司</b>从177美元到127美元。爱科股价在盘前交易中下跌 1%，至 112.95 美元。</li><li>加拿大皇家银行资本筹集<b>联合爱迪生公司。</b>目标价从78美元到85美元。周二，爱迪生联合股价下跌 0.8%，收于 83.37 美元。</li><li>奥本海默切割<b>百健公司。</b>目标价从390美元到350美元。百健股价在盘前交易中下跌 0.1%，至 234.50 美元。</li></ul></blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Biggest Price Target Changes For Wednesday<blockquote>周三 10 大价格目标变化</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Biggest Price Target Changes For Wednesday<blockquote>周三 10 大价格目标变化</blockquote>\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga Earnings </p>\n<p class=\"h-time smaller\">2021-12-22 21:56</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<p><ul>  <li>Barclays lifted the price target on&nbsp;<b>FactSet Research Systems Inc.</b>&nbsp;from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.</li>  <li>HC Wainwright &amp; Co. raised the price target on&nbsp;<b>Chimerix, Inc.</b>&nbsp;from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.</li>  <li>Bernstein raised&nbsp;<b>PACCAR Inc</b>&nbsp;price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>Adagio Therapeutics, Inc.</b>&nbsp;price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.</li>  <li>Barclays boosted the price target for&nbsp;<b>NIKE, Inc.</b>&nbsp;from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.</li>  <li>Needham lowered the price target on&nbsp;<b>Cognyte Software Ltd.</b>&nbsp;from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.</li>  <li>Jefferies cut&nbsp;<b>ALX Oncology Holdings Inc.</b>&nbsp;price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.</li>  <li>Bernstein reduced the price target for&nbsp;<b>AGCO Corporation</b>&nbsp;from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.</li>  <li>RBC Capital raised&nbsp;<b>Consolidated Edison, Inc.</b>&nbsp;price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.</li>  <li>Oppenheimer cut&nbsp;<b>Biogen Inc.</b>&nbsp;price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.</li> </ul></p><p><blockquote><ul><li>巴克莱上调目标价<b>事实集研究系统公司。</b>从450美元到550美元。FactSet Research 股价在盘前交易中上涨 1.1%，至 479.89 美元。</li><li>HC Wainwright &amp; Co. 上调目标价<b>奇美里克斯公司。</b>从21美元到24美元。Chimerix 股价在盘前交易中上涨 4.4%，至 6.42 美元。</li><li>伯恩斯坦提出<b>帕卡公司</b>目标价从94美元到98美元。PACCAR 股价在盘前交易中上涨 0.8%，至 84.04 美元。</li><li>杰富瑞切割<b>柔板治疗公司。</b>目标价从46美元到10美元。Adagio Therapeutics 股价在盘前交易中下跌 7.3%，至 9.54 美元。</li><li>巴克莱提高了目标价<b>耐克公司。</b>从185美元到195美元。耐克股价在盘前交易中上涨 0.2%，至 166.98 美元。</li><li>李约瑟下调了目标价<b>认知软件有限公司</b>从36美元到19美元。Cognyte Software 股价在盘前交易中下跌 1%，至 15.54 美元。</li><li>杰富瑞切割<b>ALX肿瘤控股公司。</b>目标价从65美元到25美元。ALX Oncology Holdings 股价在盘前交易中下跌 1.5%，至 22.57 美元。</li><li>伯恩斯坦下调了目标价<b>爱科公司</b>从177美元到127美元。爱科股价在盘前交易中下跌 1%，至 112.95 美元。</li><li>加拿大皇家银行资本筹集<b>联合爱迪生公司。</b>目标价从78美元到85美元。周二，爱迪生联合股价下跌 0.8%，收于 83.37 美元。</li><li>奥本海默切割<b>百健公司。</b>目标价从390美元到350美元。百健股价在盘前交易中下跌 0.1%，至 234.50 美元。</li></ul></blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"FDS":"辉盛研究系统","ED":"爱迪生联合电气","BIIB":"渤健公司","ALXO":"ALX Oncology Holdings","PCAR":"帕卡","CGNT":"Cognyte Software Ltd.","NKE":"耐克","AGCO":"爱科集团"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1188142807","content_text":"Barclays lifted the price target on FactSet Research Systems Inc. from $450 to $550. FactSet Research shares rose 1.1% to $479.89 in pre-market trading.\nHC Wainwright & Co. raised the price target on Chimerix, Inc. from $21 to $24. Chimerix shares rose 4.4% to $6.42 in pre-market trading.\nBernstein raised PACCAR Inc price target from $94 to $98. PACCAR shares rose 0.8% to $84.04 in pre-market trading.\nJefferies cut Adagio Therapeutics, Inc. price target from $46 to $10. Adagio Therapeutics shares dipped 7.3% to $9.54 in pre-market trading.\nBarclays boosted the price target for NIKE, Inc. from $185 to $195. NIKE shares rose 0.2% to $166.98 in pre-market trading.\nNeedham lowered the price target on Cognyte Software Ltd. from $36 to $19. Cognyte Software shares fell 1% to $15.54 in pre-market trading.\nJefferies cut ALX Oncology Holdings Inc. price target from $65 to $25. ALX Oncology Holdings shares fell 1.5% to $22.57 in pre-market trading.\nBernstein reduced the price target for AGCO Corporation from $177 to $127. AGCO shares fell 1% to $112.95 in pre-market trading.\nRBC Capital raised Consolidated Edison, Inc. price target from $78 to $85. Consolidated Edison shares fell 0.8% to close at $83.37 on Tuesday.\nOppenheimer cut Biogen Inc. price target from $390 to $350. Biogen shares fell 0.1% to $234.50 in pre-market trading.","news_type":1,"symbols_score_info":{"ALXO":0.9,"BIIB":0.9,"NKE":0.9,"PCAR":0.9,"FDS":0.9,"AGCO":0.9,"ED":0.9,"CGNT":0.9,"ADGI":0.9,"CMRX":0.9}},"isVote":1,"tweetType":1,"viewCount":3575,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626406,"gmtCreate":1640185907845,"gmtModify":1640185907845,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"title":"","htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626406","repostId":"1163953446","repostType":4,"repost":{"id":"1163953446","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640182473,"share":"https://www.laohunote.com/m/news/1163953446?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:14","market":"us","language":"en","title":"Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1163953446","media":"Tiger Newspress","summary":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-s","content":"<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos 继续下滑，盘前下跌 87.4%，此前昨天宣布其后期研究 KRYPTOS 和 ENIGMA 2 未能达到统计显著性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究符合其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至大盘。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但在两项研究中未能达到患者报告症状的共同主要终点，这引发了人们对这些组织学改善是否可以转化为临床改善的疑问。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于 lirentelimab 的表现不如安慰剂，显然存在一个问题，即为什么 II 期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen 分析师 Joseph Thome 还将 Allakos 的建议从跑赢大盘下调至市场表现，但目标价 (PT) 尚待管道明朗。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink 分析师 Thomas Smith 将该股评级从跑赢大盘下调至大盘，PT 为 17 美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>巴克莱银行分析师 Carter Gould 将该公司对 Allakos 的市盈率从 36 美元下调至 8 美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败。他认为这是lirentelimab的“终局”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos 令人失望的数据增加了嗜酸性粒细胞性胃肠道疾病 (EGIDs) 的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>Jefferies 分析师 Maury Raycroft 将 Allakos 的评级从“买入”下调至“持有”。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital 分析师 Samuel Slutsky 将该股评级从跑赢大盘下调至大盘。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Allakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAllakos slumps 87%, draws analysts downgrade on 'disappointing' lirentelimab data<blockquote>Allakos 股价暴跌 87%，分析师因 lirentelimab 数据“令人失望”而下调评级</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Allakos&nbsp;continues to slide,&nbsp;falls 87.4% premarket&nbsp;following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.</p><p><blockquote>Allakos 继续下滑，盘前下跌 87.4%，此前昨天宣布其后期研究 KRYPTOS 和 ENIGMA 2 未能达到统计显著性。</blockquote></p><p> <img src=\"https://static.tigerbbs.com/961eae374dfe4dd479394caaf470012c\" tg-width=\"714\" tg-height=\"590\" width=\"100%\" height=\"auto\"></p><p><blockquote></blockquote></p><p> The studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.</p><p><blockquote>这些研究符合其组织学共同主要终点，但未能达到症状终点。</blockquote></p><p> In ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).</p><p><blockquote>在ENIGMA中，接受lirentelimab治疗的患者在第23-24周的总症状评分-6（TSS-6）较基线降低了10.0分（基线=29.5），而安慰剂组降低了11.5分（基线=27.7；p=0.343）。</blockquote></p><p> On the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.</p><p><blockquote>在KRYPTOS试验中患者报告的吞咽困难症状问卷绝对平均变化的第二个共同主要终点上，高剂量组实现了17.4分的降低，低剂量组实现了11.9分的降低，安慰剂实现了14.6分的降低。</blockquote></p><p> Following this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.</p><p><blockquote>在这一令人失望的结果之后，几位分析师下调了该股的评级并大幅下调了目标价。</blockquote></p><p> William Blair downgraded the stock to Market Perform from Outperform.</p><p><blockquote>威廉·布莱尔将该股评级从跑赢大盘下调至大盘。</blockquote></p><p> Analysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"</p><p><blockquote>该公司分析师表示，“虽然我们相信lirentelimab已显示出针对嗜酸性粒细胞和肥大细胞的组织学活性的明确证据，但在两项研究中未能达到患者报告症状的共同主要终点，这引发了人们对这些组织学改善是否可以转化为临床改善的疑问。”</blockquote></p><p> With lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.</p><p><blockquote>分析师指出，由于 lirentelimab 的表现不如安慰剂，显然存在一个问题，即为什么 II 期的干净结果没有转化。</blockquote></p><p> Cowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.</p><p><blockquote>Cowen 分析师 Joseph Thome 还将 Allakos 的建议从跑赢大盘下调至市场表现，但目标价 (PT) 尚待管道明朗。</blockquote></p><p> SVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.</p><p><blockquote>SVB Leerink 分析师 Thomas Smith 将该股评级从跑赢大盘下调至大盘，PT 为 17 美元。</blockquote></p><p> Barclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.</p><p><blockquote>巴克莱银行分析师 Carter Gould 将该公司对 Allakos 的市盈率从 36 美元下调至 8 美元，并维持跑输大盘评级。古尔德在一份研究报告中告诉投资者，该公司的主要资产在关键的第三阶段研究中失败。他认为这是lirentelimab的“终局”。</blockquote></p><p> Morgan Stanley says Allakos' disappointing data increase&nbsp;eosinophilic gastrointestinal diseases (EGIDs) uncertainty.</p><p><blockquote>摩根士丹利表示，Allakos 令人失望的数据增加了嗜酸性粒细胞性胃肠道疾病 (EGIDs) 的不确定性。</blockquote></p><p> Jefferies analyst Maury Raycroft cut the recommendation on&nbsp;Allakos&nbsp;to Hold from Buy.</p><p><blockquote>Jefferies 分析师 Maury Raycroft 将 Allakos 的评级从“买入”下调至“持有”。</blockquote></p><p> LifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.</p><p><blockquote>LifeSci Capital 分析师 Samuel Slutsky 将该股评级从跑赢大盘下调至大盘。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1163953446","content_text":"Allakos continues to slide, falls 87.4% premarket following yesterday's announcement that its late-stage studies, KRYPTOS and ENIGMA 2failed to achieve statistical significance.\n\nThe studies met their histologic co-primary endpoints but failed to achieve symptomatic endpoints.\nIn ENIGMA, patients treated with lirentelimab achieved a 10.0-point reduction in Total Symptom Score-6 (TSS-6) at weeks 23-24 from baseline (baseline = 29.5) compared to an 11.5-point reduction in the placebo group (baseline = 27.7; p=0.343).\nOn the second co-primary endpoint of absolute mean change in patient reported Dysphagia Symptom Questionnaire in KRYPTOS trial, the high-dose group achieved a 17.4-point reduction, the low-dose group achieved an 11.9-point reduction and placebo achieved a 14.6-point reduction.\nFollowing this disappointing result, several analysts lowered their ratings of the stock and slashed the price targets.\nWilliam Blair downgraded the stock to Market Perform from Outperform.\nAnalysts of the firm say, \"while we believe lirentelimab has shown clear evidence of histologic activity against eosinophils and mast cells, the failure to achieve co-primary endpoints of patient reported symptoms in both studies raises questions about whether these histologic improvements can translate into clinical improvements.\"\nWith lirentelimab performing worse than placebo, there are clearly questions as to why the clean results in Phase II didn’t translate, the analyst notes.\nCowen analyst Joseph Thome has also cut the recommendation on Allakos to Market Perform from Outperform without the price target (PT) pending pipeline clarity.\nSVB Leerink analyst Thomas Smith downgraded the stock to Market Perform from Outperform, with PT of $17.\nBarclays analyst Carter Gould lowered the firm's PT on Allakos to $8 from $36 and keeps an Underweight rating. The company's lead asset failed in key Phase 3 studies, Gould tells investors in a research note. He views this as the \"end game\" for lirentelimab.\nMorgan Stanley says Allakos' disappointing data increase eosinophilic gastrointestinal diseases (EGIDs) uncertainty.\nJefferies analyst Maury Raycroft cut the recommendation on Allakos to Hold from Buy.\nLifeSci Capital analyst Samuel Slutsky downgraded the stock to Market Perform from Outperform.","news_type":1,"symbols_score_info":{"ALLK":0.9}},"isVote":1,"tweetType":1,"viewCount":2837,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626231,"gmtCreate":1640185895252,"gmtModify":1640185895301,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"title":"","htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/691626231","repostId":"1157274137","repostType":4,"repost":{"id":"1157274137","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1640183410,"share":"https://www.laohunote.com/m/news/1157274137?lang=zh_CN&edition=full","pubTime":"2021-12-22 22:30","market":"us","language":"en","title":"Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>","url":"https://stock-news.laohu8.com/highlight/detail?id=1157274137","media":"Tiger Newspress","summary":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes ra","content":"<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p><p><blockquote>周三股市涨跌互现，周二盘后企稳，主要股指在连续三个交易日下跌后反弹。标普500、道琼斯指数和纳斯达克指数开盘小幅下跌。</blockquote></p><p> With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p><p><blockquote>由于假期缩短的一周内交易量相对较少，投资者继续评估奥密克戎变体的众多发展及其对经济活动的潜在影响。这些更新伴随着美联储明年收紧货币政策的预期。</blockquote></p><p> Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p><p><blockquote>奥密克戎病毒已超过其他冠状病毒变种，成为美国的主要毒株，目前约占新感染病例的四分之三。在此背景下，乔·拜登总统周二宣布了一系列应对该病毒的新措施，包括开设更多联邦 COVID-19 检测和疫苗接种点，并从下个月开始向美国人免费发送 5 亿份家庭快速检测。</blockquote></p><p> \"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p><p><blockquote>SoFi 投资策略主管 Liz Young 周二对雅虎财经直播表示：“我认为现在是提醒大家市场是领先指标的绝佳时机。所以市场会下跌，市场会在坏消息达到顶峰之前触底。”“我们可能还没有听到所有的坏消息。奥密克戎的病例肯定还没有达到顶峰。”</blockquote></p><p> \"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p><p><blockquote>“但我们在（周二）的行动中看到的是，我们已经经历了三天的抛售。我认为其中一些做得太过分了，特别是在许多在重新开放环境中表现良好的领域，”她补充道。“你必须在市场上有一些资金，这些领域应该以特定方式表现良好。航空公司就是其中之一，周期性公司更多。当我们看到今天的市场模式时，我认为这对于未来 6 到 12 个月的情况来说是有道理的。”</blockquote></p><p> Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p><p><blockquote>其他策略师一致认为，投资者应该为年底出现更多波动做好准备。</blockquote></p><p> \"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p><p><blockquote>富国银行证券股票策略师 Anna Han 周二告诉雅虎财经直播：“我认为，在经历了几个动荡的交易日之后，你自然会感受到一点这种反弹。但市场也在试图对我们在这里获得的新信息进行定价和消化。”我们有一些关于重建更好的消息被推迟了，我们有更多关于奥密克戎的信息。随着年底的临近，你会看到这些事情与低流动性结合在一起，因此我们对这种波动并不感到惊讶。”</blockquote></p><p> During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p><p><blockquote>在周二发表讲话的问答环节中，拜登表示，他和参议员乔·曼钦（民主党，西弗吉尼亚州）将在白宫约1.8万亿美元的重建更好的社会政策法案上“做点什么”。曼钦本周早些时候告诉福克斯新闻频道，他不能支持这项立法，部分原因是对通货膨胀的担忧，这表明如果没有温和派民主党议员的支持，该法案将被搁置。</blockquote></p><p></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote></title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks trade mixed after rally, with tech under pressure<blockquote>股市反弹后涨跌互现，科技股承压</blockquote>\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time smaller\">2021-12-22 22:30</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&amp;P 500, Dow and Nasdaq opened in slightly negative territory.</p><p><blockquote>周三股市涨跌互现，周二盘后企稳，主要股指在连续三个交易日下跌后反弹。标普500、道琼斯指数和纳斯达克指数开盘小幅下跌。</blockquote></p><p> With trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.</p><p><blockquote>由于假期缩短的一周内交易量相对较少，投资者继续评估奥密克戎变体的众多发展及其对经济活动的潜在影响。这些更新伴随着美联储明年收紧货币政策的预期。</blockquote></p><p> Omicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now&nbsp;accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests&nbsp;to Americans for free beginning next month.</p><p><blockquote>奥密克戎病毒已超过其他冠状病毒变种，成为美国的主要毒株，目前约占新感染病例的四分之三。在此背景下，乔·拜登总统周二宣布了一系列应对该病毒的新措施，包括开设更多联邦 COVID-19 检测和疫苗接种点，并从下个月开始向美国人免费发送 5 亿份家庭快速检测。</blockquote></p><p> \"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"</p><p><blockquote>SoFi 投资策略主管 Liz Young 周二对雅虎财经直播表示：“我认为现在是提醒大家市场是领先指标的绝佳时机。所以市场会下跌，市场会在坏消息达到顶峰之前触底。”“我们可能还没有听到所有的坏消息。奥密克戎的病例肯定还没有达到顶峰。”</blockquote></p><p> \"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"</p><p><blockquote>“但我们在（周二）的行动中看到的是，我们已经经历了三天的抛售。我认为其中一些做得太过分了，特别是在许多在重新开放环境中表现良好的领域，”她补充道。“你必须在市场上有一些资金，这些领域应该以特定方式表现良好。航空公司就是其中之一，周期性公司更多。当我们看到今天的市场模式时，我认为这对于未来 6 到 12 个月的情况来说是有道理的。”</blockquote></p><p> Other strategists agreed that investors should brace for more choppiness heading into the end of the year.</p><p><blockquote>其他策略师一致认为，投资者应该为年底出现更多波动做好准备。</blockquote></p><p> \"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"</p><p><blockquote>富国银行证券股票策略师 Anna Han 周二告诉雅虎财经直播：“我认为，在经历了几个动荡的交易日之后，你自然会感受到一点这种反弹。但市场也在试图对我们在这里获得的新信息进行定价和消化。”我们有一些关于重建更好的消息被推迟了，我们有更多关于奥密克戎的信息。随着年底的临近，你会看到这些事情与低流动性结合在一起，因此我们对这种波动并不感到惊讶。”</blockquote></p><p> During a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.</p><p><blockquote>在周二发表讲话的问答环节中，拜登表示，他和参议员乔·曼钦（民主党，西弗吉尼亚州）将在白宫约1.8万亿美元的重建更好的社会政策法案上“做点什么”。曼钦本周早些时候告诉福克斯新闻频道，他不能支持这项立法，部分原因是对通货膨胀的担忧，这表明如果没有温和派民主党议员的支持，该法案将被搁置。</blockquote></p><p></p>\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".IXIC":"NASDAQ Composite",".SPX":"S&P 500 Index",".DJI":"道琼斯"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1157274137","content_text":"Stocks traded mixed on Wednesday to steady after Tuesday's session, when the major equity indexes rallied after three consecutive sessions of declines. The S&P 500, Dow and Nasdaq opened in slightly negative territory.\nWith trading volume relatively light during the holiday-shortened week, investors have continued to assess a multitude of developments on the Omicron variant and its potential impact on economic activity. These updates have come alongside expectations for tighter monetary policy next year from the Federal Reserve.\nOmicron has overtaken other coronavirus variants to become the dominant strain in the U.S., and now accounts for about three-quarters of new infections.Against this backdrop,President Joe Biden on Tuesday announced a series of new measures to address the virus, including opening additional federal COVID-19 testing and vaccination sites and sending500 million at-home rapid tests to Americans for free beginning next month.\n\"I think this is a perfect time to remind everybody that the market is a leading indicator. So the market is going to go down, the market is going to bottom before the bad news peaks,\" Liz Young, SoFi head of investment strategy, told Yahoo Finance Live on Tuesday. \"We likely haven't heard all of the bad news yet. We certainly haven't hit a peak in the Omicron cases.\"\n\"But what we're seeing in the action [Tuesday] is that, we've had three days of a sell-off. And some of that I think was overdone, especially in a lot of these areas that are positioned to do well in a reopening environment,\" she added. \"You have to have some money in the market in areas that should do well in that particular way. Airlines are one of those, cyclicals are more of those. When we look at the pattern in the market today, I think this makes sense for what's ahead for the next 6 to 12 months.\"\nOther strategists agreed that investors should brace for more choppiness heading into the end of the year.\n\"I think you naturally are getting a little bit of this bounce after we've had a couple choppy sessions. But also the market is trying to price and digest the new information we're getting here,\" Anna Han, Wells Fargo securities equity strategist,told Yahoo Finance Live on Tuesday.\"We had some news on Build Back Better getting delayed, we have more information on Omicron. These are the things you're seeing combine with low liquidity as we get into year-end, so we're not surprised to see the volatility.\"\nDuring a question and answer session during his remarks Tuesday, Biden said he and Senator Joe Manchin (D., W. Va.) were \"going to get something done\" on the White House's about $1.8 trillion Build Back Better social policy bill. Manchin had told Fox News earlier this week he could not back the legislation in part given persistent inflation concerns, suggesting the bill would be scuttled in absence of support from the moderate Democratic lawmaker.","news_type":1,"symbols_score_info":{".SPX":0.9,".DJI":0.9,".IXIC":0.9}},"isVote":1,"tweetType":1,"viewCount":3265,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":691626151,"gmtCreate":1640185863507,"gmtModify":1640185863507,"author":{"id":"4089174425482880","authorId":"4089174425482880","name":"4f4c837","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4089174425482880","idStr":"4089174425482880"},"themes":[],"title":"","htmlText":"Interesting","listText":"Interesting","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/691626151","repostId":"2193419144","repostType":4,"isVote":1,"tweetType":1,"viewCount":4003,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"defaultTab":"posts","isTTM":false}